Evolocumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PCSK9 |
| Clinical data | |
| Pronunciation | e-voe-LOK-ue-mab |
| Trade names | Repatha |
| Other names | AMG-145[1] |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6242H9648N1668O1996S56 |
| Molar mass | 141790.89 g·mol−1 |
Evolocumab,[6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver's ability to remove LDL-C, often colloquially referred to as "bad" cholesterol, from the blood.[7][8]
- ^ Sheridan C (December 2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology. 31 (12): 1057–1058. doi:10.1038/nbt1213-1057. PMID 24316621. S2CID 34214247.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
- ^ "Repatha- evolocumab injection, solution Repatha- evolocumab kit". DailyMed. U.S. National Library of Medicine. 6 May 2020. Retrieved 20 October 2020.
- ^ "Repatha EPAR". European Medicines Agency. 17 July 2015. Retrieved 29 June 2024.
- ^ World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
- ^ Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M (20 May 2022). "A Comprehensive Review of PCSK9 Inhibitors". Journal of Cardiovascular Pharmacology and Therapeutics. 27: 10742484221100107. doi:10.1177/10742484221100107. PMID 35593194. S2CID 248918656.
- ^ Weinreich M, Frishman WH (2014). "Antihyperlipidemic therapies targeting PCSK9". Cardiology in Review. 22 (3): 140–146. doi:10.1097/CRD.0000000000000014. PMID 24407047. S2CID 2201087.